The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer.

In addition to physiologic activities in the reproductive, skeletal, and central nervous systems, estrogens have been shown to play important roles in the aberrant cell proliferation observed in breast and reproductive tract cancers. Not surprisingly, pharmaceuticals that target different steps in the estrogen signal transduction pathway have found widespread use in the treatment of a wide variety of estrogen-linked disorders. The goal of this review is to outline what is known about the molecular pharmacology of the estrogen receptor and discuss how this information can be used to guide selection of drugs for a particular therapeutic application, and identify new targets where pharmaceutical exploitation could yield novel therapeutics.

[1]  D. McDonnell,et al.  The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. , 1999, Endocrinology.

[2]  B. O’Malley,et al.  Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. , 1993, Molecular endocrinology.

[3]  R B Mazess,et al.  Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.

[4]  D. McDonnell,et al.  The Estrogen Receptor ␤-isoform (er␤) of the Human Estrogen Receptor Modulates Er␣ Transcriptional Activity and Is a Key Regulator of the Cellular Response to Estrogens and Antiestrogens* , 2022 .

[5]  R. Mansel,et al.  Expression of peroxisome‐proliferator activated receptor‐gamma (PPARγ) and the PPARγ co‐activator, PGC‐1, in human breast cancer correlates with clinical outcomes , 2003, International journal of cancer.

[6]  M Carlquist,et al.  Structural insights into the mode of action of a pure antiestrogen. , 2001, Structure.

[7]  Takashi Suzuki,et al.  Estrogen-Related Receptor α in Human Breast Carcinoma as a Potent Prognostic Factor , 2004, Cancer Research.

[8]  A. Wakeling,et al.  A potent specific pure antiestrogen with clinical potential. , 1991, Cancer research.

[9]  A. Howell,et al.  The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. , 2004, Best practice & research. Clinical endocrinology & metabolism.

[10]  B Stein,et al.  Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta , 1995, Molecular and cellular biology.

[11]  Bert W O'Malley,et al.  Coregulator function: a key to understanding tissue specificity of selective receptor modulators. , 2004, Endocrine reviews.

[12]  K. Horwitz.  When tamoxifen turns bad. , 1995, Endocrinology.

[13]  R. Lanz,et al.  Nuclear receptor coregulators: cellular and molecular biology. , 1999, Endocrine reviews.

[14]  B. O’Malley,et al.  Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D. Heitjan,et al.  Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. , 1995, The Journal of clinical endocrinology and metabolism.

[16]  J. Bryant,et al.  Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. , 2001, Journal of the National Cancer Institute.

[17]  T. Willson,et al.  Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. , 2001, Cancer research.

[18]  D. Fowlkes,et al.  Peptide antagonists of the human estrogen receptor. , 1999, Science.

[19]  S. Hilsenbeck,et al.  Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.

[20]  K.,et al.  A new derivative of triphenylethylene: effect on implantation and mode of action in rats. , 1967, Journal of reproduction and fertility.

[21]  H Grøn,et al.  Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Meltzer,et al.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.

[24]  M Carlquist,et al.  Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist , 1999, The EMBO journal.

[25]  D. Fowlkes,et al.  Comparative analyses of mechanistic differences among antiestrogens. , 1999, Endocrinology.

[26]  K. Korach,et al.  Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. , 1996, Endocrinology.

[27]  J. Gustafsson,et al.  Cloning of a novel estrogen receptor expressed in rat prostate and ovary , 2022 .

[28]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[29]  A. Brodie.  Aromatase inhibitors in breast cancer , 2002, Trends in Endocrinology & Metabolism.

[30]  B. Komm,et al.  Evaluation of an Estrogen Receptor-β Agonist in Animal Models of Human Disease , 2003 .

[31]  E. Jensen,et al.  Estrogen receptor (ER) , a modulator of ER in the uterus , 2000 .

[32]  J. Pike,et al.  Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. , 1995, Molecular endocrinology.

[33]  M. Conaway,et al.  Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. , 2002, Endocrinology.

[34]  D. Fowlkes,et al.  Comparative Analyses of Mechanistic Differences Among Antiestrogens1. , 1999, Endocrinology.

[35]  J. York,et al.  Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Edwards,et al.  Rapid extranuclear signaling by the estrogen receptor (ER): MNAR couples ER and Src to the MAP kinase signaling pathway. , 2003, Molecular interventions.

[37]  P. Chambon,et al.  Estrogen receptor-α mediates the brain antiinflammatory activity of estradiol , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Edwards,et al.  Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. , 1992, The Journal of biological chemistry.

[39]  A. Howell,et al.  Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer , 1995, The Lancet.

[40]  S. Robinson,et al.  Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. , 1988, Journal of steroid biochemistry.

[41]  L. Moore,et al.  3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats. , 1994, Journal of medicinal chemistry.

[42]  B. O’Malley,et al.  Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. , 1997, Molecular endocrinology.

[43]  E. Ariazi,et al.  Estrogen-related Receptor α and Estrogen-related Receptor γ Associate with Unfavorable and Favorable Biomarkers, Respectively, in Human Breast Cancer , 2002 .

[44]  Myles Brown,et al.  Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.

[45]  D. McDonnell,et al.  The Molecular Pharmacology of SERMs , 1999, Trends in Endocrinology & Metabolism.

[46]  Richard G. W. Anderson,et al.  Has Nongenomic Action in Caveolae , 2002 .

[47]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[48]  D. McDonnell,et al.  The Human Estrogen Receptor-α Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators* , 2001, The Journal of Biological Chemistry.

[49]  H. Broxmeyer,et al.  Increased osteoclast development after estrogen loss: mediation by interleukin-6. , 1992, Science.

[50]  T. Willson,et al.  Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. , 1997, Endocrinology.

[51]  Robert J Cersosimo,et al.  Tamoxifen for Prevention of Breast Cancer , 2003 .